vs
Certara, Inc.（CERT）与Tarsus Pharmaceuticals, Inc.（TARS）财务数据对比。点击上方公司名可切换其他公司
Tarsus Pharmaceuticals, Inc.的季度营收约是Certara, Inc.的1.4倍（$151.7M vs $106.9M），Tarsus Pharmaceuticals, Inc.净利率更高（-5.5% vs -8.2%，领先2.7%），Tarsus Pharmaceuticals, Inc.同比增速更快（128.4% vs 0.8%），过去两年Tarsus Pharmaceuticals, Inc.的营收复合增速更高（134.4% vs 7.0%）
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
Tarsus Pharmaceuticals是一家处于后期临床阶段的生物制药公司，专注于眼科、皮肤科等专科领域创新疗法的研发和商业化，主打产品针对蠕形螨睑缘炎、玫瑰痤疮等未被充分诊断的常见病症，核心市场为美国。
CERT vs TARS — 直观对比
营收规模更大
TARS
是对方的1.4倍
$106.9M
营收增速更快
TARS
高出127.5%
0.8%
净利率更高
TARS
高出2.7%
-8.2%
两年增速更快
TARS
近两年复合增速
7.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $106.9M | $151.7M |
| 净利润 | $-8.8M | $-8.4M |
| 毛利率 | 61.1% | — |
| 营业利润率 | 34.9% | -5.3% |
| 净利率 | -8.2% | -5.5% |
| 营收同比 | 0.8% | 128.4% |
| 净利润同比 | -287.2% | 63.8% |
| 每股收益（稀释后） | $-0.06 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CERTTARS
| Q1 26 | $106.9M | — | ||
| Q4 25 | $103.6M | $151.7M | ||
| Q3 25 | $104.6M | $118.7M | ||
| Q2 25 | $104.6M | $102.7M | ||
| Q1 25 | $106.0M | $78.3M | ||
| Q4 24 | $100.4M | $66.4M | ||
| Q3 24 | $94.8M | $48.1M | ||
| Q2 24 | $93.3M | $40.8M |
净利润CERTTARS
| Q1 26 | $-8.8M | — | ||
| Q4 25 | $-5.9M | $-8.4M | ||
| Q3 25 | $1.5M | $-12.6M | ||
| Q2 25 | $-2.0M | $-20.3M | ||
| Q1 25 | $4.7M | $-25.1M | ||
| Q4 24 | $6.6M | $-23.1M | ||
| Q3 24 | $-1.4M | $-23.4M | ||
| Q2 24 | $-12.6M | $-33.3M |
毛利率CERTTARS
| Q1 26 | 61.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率CERTTARS
| Q1 26 | 34.9% | — | ||
| Q4 25 | 0.8% | -5.3% | ||
| Q3 25 | 2.9% | -12.2% | ||
| Q2 25 | 9.1% | -21.6% | ||
| Q1 25 | 7.2% | -33.5% | ||
| Q4 24 | 6.0% | -36.8% | ||
| Q3 24 | 2.7% | -52.3% | ||
| Q2 24 | -9.7% | -81.6% |
净利率CERTTARS
| Q1 26 | -8.2% | — | ||
| Q4 25 | -5.7% | -5.5% | ||
| Q3 25 | 1.5% | -10.6% | ||
| Q2 25 | -1.9% | -19.8% | ||
| Q1 25 | 4.5% | -32.1% | ||
| Q4 24 | 6.6% | -34.8% | ||
| Q3 24 | -1.4% | -48.7% | ||
| Q2 24 | -13.5% | -81.6% |
每股收益（稀释后）CERTTARS
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $-0.04 | $-0.17 | ||
| Q3 25 | $0.01 | $-0.30 | ||
| Q2 25 | $-0.01 | $-0.48 | ||
| Q1 25 | $0.03 | $-0.64 | ||
| Q4 24 | $0.04 | $-0.57 | ||
| Q3 24 | $-0.01 | $-0.61 | ||
| Q2 24 | $-0.08 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.5M | $417.3M |
| 总债务越低越好 | $3.0M | $72.4M |
| 股东权益账面价值 | $1.0B | $343.4M |
| 总资产 | $1.5B | $562.2M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资CERTTARS
| Q1 26 | $149.5M | — | ||
| Q4 25 | $189.4M | $417.3M | ||
| Q3 25 | $172.7M | $401.8M | ||
| Q2 25 | $162.3M | $381.1M | ||
| Q1 25 | $179.1M | $407.9M | ||
| Q4 24 | $179.2M | $291.4M | ||
| Q3 24 | $233.0M | $317.0M | ||
| Q2 24 | $224.6M | $323.6M |
总债务CERTTARS
| Q1 26 | $3.0M | — | ||
| Q4 25 | $293.1M | $72.4M | ||
| Q3 25 | $293.5M | $72.3M | ||
| Q2 25 | $294.2M | $72.1M | ||
| Q1 25 | $294.8M | $72.0M | ||
| Q4 24 | $295.4M | $71.8M | ||
| Q3 24 | $296.1M | $71.7M | ||
| Q2 24 | $296.7M | $71.6M |
股东权益CERTTARS
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.1B | $343.4M | ||
| Q3 25 | $1.1B | $335.1M | ||
| Q2 25 | $1.1B | $332.6M | ||
| Q1 25 | $1.1B | $342.5M | ||
| Q4 24 | $1.1B | $224.5M | ||
| Q3 24 | $1.1B | $237.5M | ||
| Q2 24 | $1.0B | $252.2M |
总资产CERTTARS
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.6B | $562.2M | ||
| Q3 25 | $1.5B | $534.6M | ||
| Q2 25 | $1.5B | $495.0M | ||
| Q1 25 | $1.6B | $500.8M | ||
| Q4 24 | $1.6B | $377.0M | ||
| Q3 24 | $1.5B | $376.3M | ||
| Q2 24 | $1.5B | $376.8M |
负债/权益比CERTTARS
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.28× | 0.21× | ||
| Q3 25 | 0.28× | 0.22× | ||
| Q2 25 | 0.27× | 0.22× | ||
| Q1 25 | 0.27× | 0.21× | ||
| Q4 24 | 0.28× | 0.32× | ||
| Q3 24 | 0.28× | 0.30× | ||
| Q2 24 | 0.28× | 0.28× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.7M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | — | $13.0M |
| 自由现金流率自由现金流/营收 | — | 8.6% |
| 资本支出强度资本支出/营收 | 0.6% | 4.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-22.3M |
8季度趋势，按日历期对齐
经营现金流CERTTARS
| Q1 26 | $11.7M | — | ||
| Q4 25 | $28.8M | $19.3M | ||
| Q3 25 | $32.3M | $18.3M | ||
| Q2 25 | $17.8M | $-29.4M | ||
| Q1 25 | $17.4M | $-20.7M | ||
| Q4 24 | $49.4M | $-22.2M | ||
| Q3 24 | $17.0M | $-8.7M | ||
| Q2 24 | $9.8M | $-14.4M |
自由现金流CERTTARS
| Q1 26 | — | — | ||
| Q4 25 | $27.8M | $13.0M | ||
| Q3 25 | $32.1M | $16.3M | ||
| Q2 25 | $17.8M | $-30.4M | ||
| Q1 25 | $16.8M | $-21.2M | ||
| Q4 24 | $49.0M | $-22.3M | ||
| Q3 24 | $16.8M | $-8.9M | ||
| Q2 24 | $9.4M | $-15.4M |
自由现金流率CERTTARS
| Q1 26 | — | — | ||
| Q4 25 | 26.8% | 8.6% | ||
| Q3 25 | 30.7% | 13.8% | ||
| Q2 25 | 17.0% | -29.6% | ||
| Q1 25 | 15.8% | -27.1% | ||
| Q4 24 | 48.8% | -33.5% | ||
| Q3 24 | 17.7% | -18.6% | ||
| Q2 24 | 10.1% | -37.8% |
资本支出强度CERTTARS
| Q1 26 | 0.6% | — | ||
| Q4 25 | 1.0% | 4.2% | ||
| Q3 25 | 0.2% | 1.6% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.6% | 0.8% | ||
| Q4 24 | 0.4% | 0.1% | ||
| Q3 24 | 0.2% | 0.6% | ||
| Q2 24 | 0.5% | 2.5% |
现金转化率CERTTARS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 21.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.66× | — | ||
| Q4 24 | 7.51× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
